Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
22 oct. 2024 16h01 HE
|
Genelux Corporation
– VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent...
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
09 oct. 2024 16h15 HE
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
03 sept. 2024 16h01 HE
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President,...
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
14 août 2024 16h05 HE
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second...
Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024
30 juil. 2024 07h00 HE
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
24 mai 2024 08h00 HE
|
Genelux Corporation
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
23 mai 2024 16h01 HE
|
Genelux Corporation
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
09 mai 2024 16h25 HE
|
Genelux Corporation
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
01 avr. 2024 07h00 HE
|
Genelux Corporation
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
27 nov. 2023 07h00 HE
|
Genelux Corporation
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer